- Conditions
- Macular Degeneration
- Interventions
- Rituximab
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 41 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 669
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Exudative Age-Related Macular Degeneration, Focal Vitreomacular Adhesion
- Interventions
- Ocriplasmin, Sham injection
- Drug
- Lead sponsor
- ThromboGenics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 12
- States / cities
- Beverly Hills, California • Sacramento, California • Aurora, Colorado + 9 more
- Conditions
- Macular Degeneration
- Interventions
- rhuFab V2 (ranibizumab)
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 70
- States / cities
- Tucson, Arizona • Beverly Hills, California • Irvine, California + 60 more
- Conditions
- Age Related Macular Degeneration
- Interventions
- Intravitreal Aflibercept injection
- Drug
- Lead sponsor
- Retina Research Institute, LLC
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • McAllen, Texas
- Conditions
- Nonexudative Age-Related Macular Degeneration, Unspecified Eye, Intermediate Dry Stage
- Interventions
- High Dose NT-501 implant, Low Dose NT-501 implant, Sham
- Combination Product · Other
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Hollywood, Florida • Miami, Florida + 5 more
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy
- Interventions
- Surgical implantation of the CPCB-RPE1 implant
- Device
- Lead sponsor
- Regenerative Patch Technologies, LLC
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2040
- U.S. locations
- 5
- States / cities
- Huntington Beach, California • Los Angeles, California • Lemont, Illinois + 2 more
- Conditions
- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
- Interventions
- bevacizumab, ranibizumab
- Biological
- Lead sponsor
- Outlook Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 50
- States / cities
- Tucson, Arizona • Arcadia, California • Beverly Hills, California + 46 more
- Conditions
- Macular Degeneration
- Interventions
- Regorafenib, ophthalmic oily suspension (BAY73-4506), Sham IVT, Ranibizumab, Placebo
- Drug · Procedure
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 37
- States / cities
- Tucson, Arizona • Arcadia, California • Beverly Hills, California + 34 more
- Conditions
- Macular Degeneration, Maculopathy, Age-Related
- Interventions
- anecortave acetate
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Age-Related Macular Degeneration
- Interventions
- DE-120, Aflibercept
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Bakersfield, California • Walnut Creek, California + 11 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- CLS-AX, Anti-VEGF
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Bakersfield, California • Mountain View, California + 8 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- 2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg DE-122 Injectable Solution + Lucentis, Lucentis
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 10
- States / cities
- Gilbert, Arizona • Beverly Hills, California • Mountain View, California + 7 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- SF0166 Topical Ophthalmic Solution
- Drug
- Lead sponsor
- OcuTerra Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Fullerton, California • Mountain View, California + 9 more
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
- Interventions
- Ixo-vec, Aflibercept
- Genetic · Drug
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 75
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 67 more
- Conditions
- Macular Degeneration
- Interventions
- Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL
- Drug
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Central Contact Fort Worth, Texas
- Conditions
- Central Retinal Vein Occlusion, Choroidal Neovascularization, Age-related Macular Degeneration, Branch Retinal Vein Occlusion
- Interventions
- Conj flora Antibiotic resistance
- Procedure
- Lead sponsor
- Mid Atlantic Retina
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Dry Age Related Macular Degeneration.
- Interventions
- Retinal transplantation instrument, Fetal tissue.
- Device
- Lead sponsor
- Radtke, Norman D., M.D.
- Individual
- Eligibility
- 55 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Sirolimus, Standard of Care intravitreal injections of anti-VEGF
- Drug
- Lead sponsor
- Maturi, Raj K., M.D., P.C.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Age Related Macular Degeneration, Cognition Disorders
- Interventions
- 3R 3'R Zeaxanthin, Lutein, Lutein and Zeaxanthin
- Drug · Dietary Supplement
- Lead sponsor
- Chrysantis, Inc.
- Industry
- Eligibility
- 45 Years to 90 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- North Chicago, Illinois
- Conditions
- Age Related Macular Degeneration
- Interventions
- carbidopa-levodopa
- Drug
- Lead sponsor
- Snyder, Robert W., M.D., Ph.D., P.C.
- Individual
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
- Interventions
- Tiespectus, Aflibercept
- Drug
- Lead sponsor
- EyeBiotech Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 960 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 52
- States / cities
- Gilbert, Arizona • Encino, California • Mountain View, California + 49 more
- Conditions
- Macular Degeneration
- Interventions
- Anecortave Acetate 15 mg sterile suspension, Photodynamic Therapy (PDT)
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Geographic Atrophy, Age-related Macular Degeneration
- Interventions
- LFG316, Sham, LFG316 Lower dose
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 15 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- PDS Implant with Ranibizumab 100 mg/mL
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 81
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 69 more